ATTN: United States Pharmacopeia
"When Congress enacted Medicare Part D, there were no widely accepted FDA-approved obesity drugs on the market. This fact, combined with the outdated misperception by many on Capitol Hill at that time that obesity was a lifestyle condition, led Congress to exclude Medicare Part D from covering “weight loss drugs.” Throughout this decade, significant medical advances have been made in the development of obesity drugs. These new medications and our country’s current and growing obesity epidemic clearly make the Part D statute no longer reflective of current scientific guidelines or current FDA approvals..."
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.